Endocrine Abstracts

Introduction: Adrenocortical carcinoma (ACC) is a rare and aggressive tumour. At diagnosis 21% has metastasis. Even after complete surgical removal, patients are at risk of recurrence as late as 10-12 years. The 5-year survival rate of Stage I to IV (ENSAT 2008) is 82%, 61%, 50% and 13% respectively.Objetive: To describe the epidemiological and clinical characteristics, as well as the evolution, treatments and overall survival of patients diagnosed with ...

Introduction: The use of Bisphosphonates could be a treatment option of osteoporosis secondary to primary hyperparathyroidism (OPHP) in patients not eligible or that refuse/reject surgery.Methods/design: We analysed data of 46 patients diagnosed of OPHP. Fourteen underwent surgery and 32 were treated with bisphosphonates at standard dose. Densitometric parameters and of calcium-phosphorus metabolism were analyzed before and after 1 and 2 years of treatme...

Introduction: The role of mitotane as an adjuvant therapy for adrenocortical carcinoma (ACC) remains a contentious topic due to the scarcity of robust randomized clinical trials, attributed to the low incidence of this neoplasm. Despite this, the prognosis following surgery for localized tumors is generally poor, leading to varied clinical practices.Methods: This study utilized patient data from the ICARO registry of the GETHY group and SEEN, with diseas...